Join the Ozempic group to help and get support from people like you.
Ozempic News (Page 11)
'Hungry Gut' Gene Test Shows Who'll Benefit Most From Wegovy
TUESDAY, May 21, 2024 – You've watched others shed pounds in a matter of weeks after taking one of the new blockbuster weight-loss drugs, so you decide to try one of the medications yourself, only...
Semaglutide Has Lasting Benefit for Weight Loss
TUESDAY, May 21, 2024 – Semaglutide has a long-term beneficial impact on weight, as well as cardiovascular benefits, regardless of weight loss, according to two studies presented at the annual...
Stomach Paralysis Risk May Rise in People Taking Ozempic and Similar Drugs
MONDAY, May 20, 2024 – New, real-world research confirms that the blockbuster weight-loss drugs that millions of Americans have been taking to shed pounds can trigger stomach paralysis in some...
Semaglutide Reduces Need for Diuretics in Heart Failure
THURSDAY, May 16, 2024 – Semaglutide reduces the need for loop diuretics and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved...
Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist
TUESDAY, May 14, 2024 – One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using one, according to...
GLP-1 Receptor Agonist Use Increases Likelihood of Antidepressant Prescription
WEDNESDAY, May 15, 2024 – Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a study published...
More Studies Support Wegovy's Long-Term Weight-Loss Benefits
TUESDAY, May 14, 2024 – Semaglutide – the active ingredient in the blockbuster weight-loss drugs Ozempic and Wegovy – can produce long-term weight and heart health benefits, a pair of new studies...
One in 8 U.S. Adults Have Now Used Blockbuster Meds Like Ozempic
FRIDAY, May 10, 2024 – About 1 in 8 U.S. adults (12%) have tried a weight-loss drug like Wegovy, Ozempic, Zepbound or Mounjaro, a new KFF Health Tracking Poll says. About 6% are taking one right...
A Cardiologist Answers Your Questions on New Weight-Loss Meds, Ozempic and Zepbound
MONDAY, Feb. 12, 2024 – Weight loss drugs like Ozempic and Zepbound can lead to better heart health for people struggling with excess weight or diabetes, a University of Michigan cardiologist says....
A Cardiologist Answers Your Questions on New Weight-Loss Meds, Ozempic and Zepbound
MONDAY, Feb. 12, 2024 – Weight loss drugs like Ozempic and Zepbound can lead to better heart health for people struggling with excess weight or diabetes, a University of Michigan cardiologist says....
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
FDA Medwatch Alert: FDA Warns Consumers Not to Use Counterfeit Ozempic (semaglutide) Found in U.S. Drug Supply Chain
December 21, 2023 – FDA continues to investigate counterfeit Ozempic (semaglutide) injection 1 milligram (mg) in the legitimate U.S. drug supply chain and has seized thousands of units of the...
FDA Medwatch Alert: FDA Issues Warning About Compounded Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss
On May 30, 2023, the FDA posted information about medications containing semaglutide marketed for type 2 diabetes or weight loss. There are currently three FDA-approved semaglutide products which are...
Novo Nordisk Receives FDA Approval of Higher-Dose Ozempic 2 mg Providing Increased Glycemic Control for Adults with Type 2 Diabetes
Ozempic® demonstrated 2.1% blood sugar reduction and also weight loss in adults with type 2 diabetes with new 2 mg dose1 PLAINSBORO, N.J., March 28, 2022 /PRNewswire/ – Novo Nordisk today ...
FDA Approves Ozempic (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease
PLAINSBORO, N.J., Jan. 16, 2020 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Ozempic (semaglutide) injection 0.5 mg...
Further information
Related condition support groups
Cardiovascular Risk Reduction, Chronic Kidney Disease, Diabetes, Type 2